CVD prevention, treatment challenging as patients with HIV and HCV live longer
FDA approves ticagrelor for long-term use after ACS event
Lipid Forum II Highlights
The Patient with Obesity
AstraZeneca announced that a 60 mg twice-daily dose of its antiplatelet agent ticagrelor has been approved by the FDA for prevention of CV death, MI and stroke in patients more than 1 year after an ACS event.
Ticagrelor (Brilinta) was previously approved in a 90 mg twice-daily dose for use in patients up to 1 year after an ACS event for prevention of CV events and stent thrombosis, according to an AstraZeneca press release.
This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC
No commercial support for this activity.
Optimal testing strategy for patients with suspected CAD remains unclear
Keith C. Ferdinand, MD, a front-runner in patient care
Novel mechanism, potential treatment strategies for CVD in patients with HIV
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.